Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
tolterodine
|
| gptkbp:approvalYear |
1998
|
| gptkbp:ATCCode |
G04BD07
|
| gptkbp:availableOn |
gptkb:tablet
extended-release capsule |
| gptkbp:brand |
tolterodine
|
| gptkbp:CASNumber |
124937-51-5
|
| gptkbp:chemicalFormula |
C22H31NO
|
| gptkbp:contraindication |
urinary retention
uncontrolled narrow-angle glaucoma gastric retention |
| gptkbp:drugClass |
antimuscarinic
|
| gptkbp:eliminationHalfLife |
2-4 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Detrol
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
constipation
dizziness headache blurred vision dry mouth |
| gptkbp:usedFor |
urinary incontinence
overactive bladder urinary frequency urinary urgency |
| gptkbp:bfsParent |
gptkb:Viatris
|
| gptkbp:bfsLayer |
8
|